The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Imaging in diagnosis and response assessment in myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the role of imaging in the diagnosis and response assessment of patients with myeloma and describes new diagnostic requirements. Dr Zamagni talks on the minimal requirement for diagnosis staging of myeloma, which is performed using whole-body low-dose computed tomography (WBLDCT), as well as the benefits of positron emission tomography (PET)-computed tomography (CT) and diffusion-weighted magnetic resonance imaging (MRI). Dr Zamagni also talks on the use of PET-CT and diffusion-weighted MRI and other novel techniques for the assessment of measurable residual disease (MRD). This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
